Maegim한국어

대화제약

067080KOSDAQSector: Pharma & Biotech
₩9,190▼ 1.18%Market cap ₩171.1BAs of Jul 21, 2026 close · updated once daily
D
Grade D38.9 ptsTop 72% of 2,523 stocks
Financial strength
35.3
Growth momentum
28.9
Price attractiveness
50.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

35.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
166.4%
✗ Below median · Top 88.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
51.3%
✗ Below median · Top 92.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
2.2%
✓ Above median · Top 40.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
2.2%
✓ Above median · Top 37.2% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

28.9
How much did revenue grow in a year?
Revenue growth (YoY)
-4.2%
✗ Below median · Top 73.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
2.7%
✗ Below median · Top 59.1% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-52.9%
✗ Below median · Top 83.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-45.9%
✗ Below median · Top 68.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

50.2
Is the price expensive relative to earnings?
P/E (price-to-earnings)
103.5x
✓ Above median · Top 38% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.31x
✗ Below median · Top 61.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15